Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12168462 | 0.81 | LMNA (0.34) | LMNAHSD17B10GAAALOX15 | |
| SCHEMBL28507146 | 0.77 | LMNA (0.38) | LMNAHSD17B10GAAALOX15 | |
| SCHEMBL224525 | 0.77 | LMNA (0.52) | LMNAHSD17B10GAAALOX15CHRM2 | |
| SCHEMBL18131107 | 0.77 | LMNA (0.38) | LMNAHSD17B10GAAALOX15TSHR | |
| SCHEMBL14049705 | 0.76 | LMNA (0.32) | LMNAHSD17B10 | |
| SCHEMBL27759481 | 0.76 | LMNA (0.36) | LMNAHSD17B10GAAALOX15 | |
| SCHEMBL16214719 | 0.76 | LMNA (0.36) | LMNAHSD17B10GAAALOX15CYP2C19 | |
| SCHEMBL16244342 | 0.74 | LMNA (0.44) | LMNAHSD17B10ALOX15TSHR | |
| SCHEMBL3077229 | 0.74 | LMNA (0.35) | LMNAHSD17B10GAAALOX15TSHR | |
| SCHEMBL27535729 | 0.74 | CYP4F2 (0.40) | LMNAHSD17B10GAAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3050883-B1 | PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVES AND INTERMEDIATES | MEIJI SEIKA PHARMA CO LTD (JP) | 2020-04-22 | — | — | EP | disclosed |
| US-10000492-B2 | Process for producing diazabicyclooctane derivative | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170283415-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2017-10-05 | — | — | US | disclosed |
| US-20160264573-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2016-09-15 | — | — | US | disclosed |
| EP-3050883-A1 | PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIARY BODY THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2016-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000492-B2 | Process for producing diazabicyclooctane derivative | OGFOD1, HAAO, CLCN2 | LMNA 1607/4885HSD17B10 292/4885GAA 3646/4885 |
| US-20170283415-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE | OGFOD1, HAAO, CLCN2 | LMNA 1607/4885HSD17B10 292/4885GAA 3646/4885 |
| US-20160264573-A1 | PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF | CLCN2, ODC1, KCNN4 | LMNA 921/4885HSD17B10 1725/4885GAA 3868/4885 |
| US-10000491-B2 | Process for producing diazabicyclooctane derivative and intermediate thereof | CLCN2, ODC1, KCNN4 | LMNA 921/4885HSD17B10 1725/4885GAA 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.